The Columbia River Community Clinical Oncology Program (CRCCOP) is an established organization of seven years duration, which has been successful in accrual of subjects to treatment and cancer control protocols, and has established an enviable record for quality of data management. Our objectives are to continue our present associations with primary and secondary research bases (Primary: Southwest Oncology Group and the National Surgical Project for Breast and Bowel Cancers, Secondary: MD Anderson Cancer Center) through currently established mechanisms and to expand and strengthen cancer control activities especially in ethnic minority populations. To this end we are continuing our participation in the NSABP Breast Cancer Prevention Trial and have been accepted by the SWOG for inclusion in the upcoming Prostate Cancer Prevention Trial. We also have recently begun to forge alliances with leaders of the African-American community (the local ministerial alliance, the local Chair of the Oregon Chapter of the National Black Leadership Initiative on Cancer, and a community activist concerned about prostate cancer). The plan is to take the program into the community with the support and assistance of leaders already identified by the community. In addition, all urologic groups in the service area enthusiastically support the PCPT trial and have agreed to place subjects on study. The cadre of investigators for cancer control activities has been broadened to include primary care physicians not only to increase accrual rates but also to initiate and strengthen the concept of primary and secondary prevention among community physicians. In the treatment arena it is now the community standard to practice evidence-based oncologic management and to participate in clinical trials if the best method of management is still unclear. This change appears to be the direct result of CCOP activities and will be continued. Several key factors have allowed the CRCCOP program to prosper. Our experienced CCOP investigators and staff have broad clinical research credentials which pre-date the initiation of CROP and which have allowed us to increase accrual to treatment and cancer control protocols. In addition, our location in the Portland, Oregon, and Southwest Washington metropolitan area offers us access to a large, otherwise untapped patient population. We have an extremely strong base of support from the participating institutions which both considerably lowers the National Cancer Institute's cost per patient and assures the CCOP of continuity. These factors, combined with out demonstrated initiative and resources, promise to provide the NCI with a strong CCOP program that continues to develop its potential.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
5U10CA045377-09
Application #
2091845
Study Section
Special Emphasis Panel (SRC (74))
Project Start
1987-08-28
Project End
1999-05-31
Budget Start
1995-09-01
Budget End
1996-05-31
Support Year
9
Fiscal Year
1995
Total Cost
Indirect Cost
Name
Providence Portland Medical Center
Department
Type
DUNS #
City
Portland
State
OR
Country
United States
Zip Code
97213
Samlowski, Wolfram E; Moon, James; Witter, Merle et al. (2017) High frequency of brain metastases after adjuvant therapy for high-risk melanoma. Cancer Med 6:2576-2585
Goldkorn, Amir; Ely, Benjamin; Tangen, Catherine M et al. (2015) Circulating tumor cell telomerase activity as a prognostic marker for overall survival in SWOG 0421: a phase III metastatic castration resistant prostate cancer trial. Int J Cancer 136:1856-62
Blumenthal, Deborah T; Rankin, Cathryn; Stelzer, Keith J et al. (2015) A Phase III study of radiation therapy (RT) and O?-benzylguanine + BCNU versus RT and BCNU alone and methylation status in newly diagnosed glioblastoma and gliosarcoma: Southwest Oncology Group (SWOG) study S0001. Int J Clin Oncol 20:650-8
Ou, Sai-Hong Ignatius; Moon, James; Garland, Linda L et al. (2015) SWOG S0722: phase II study of mTOR inhibitor everolimus (RAD001) in advanced malignant pleural mesothelioma (MPM). J Thorac Oncol 10:387-91
Budd, George T; Barlow, William E; Moore, Halle C F et al. (2015) SWOG S0221: a phase III trial comparing chemotherapy schedules in high-risk early-stage breast cancer. J Clin Oncol 33:58-64
Gralow, Julie R; Barlow, William E; Lew, Danika et al. (2014) A phase II study of docetaxel and vinorelbine plus filgrastim for HER-2 negative, stage IV breast cancer: SWOG S0102. Breast Cancer Res Treat 143:351-8
Yao, S; Sucheston, L E; Zhao, H et al. (2014) Germline genetic variants in ABCB1, ABCC1 and ALDH1A1, and risk of hematological and gastrointestinal toxicities in a SWOG Phase III trial S0221 for breast cancer. Pharmacogenomics J 14:241-7
Malhotra, Binu; Moon, James; Kucuk, Omar et al. (2014) Phase II trial of biweekly gemcitabine and paclitaxel with recurrent or metastatic squamous cell carcinoma of the head and neck: Southwest Oncology Group study S0329. Head Neck 36:1712-7
Bepler, Gerold; Zinner, Ralph G; Moon, James et al. (2014) A phase 2 cooperative group adjuvant trial using a biomarker-based decision algorithm in patients with stage I non-small cell lung cancer (SWOG-0720, NCT00792701). Cancer 120:2343-51
Flaherty, Lawrence E; Othus, Megan; Atkins, Michael B et al. (2014) Southwest Oncology Group S0008: a phase III trial of high-dose interferon Alfa-2b versus cisplatin, vinblastine, and dacarbazine, plus interleukin-2 and interferon in patients with high-risk melanoma--an intergroup study of cancer and leukemia Group B, Ch J Clin Oncol 32:3771-8

Showing the most recent 10 out of 142 publications